Health Canada has finalized the second phase of its modernization of the Medical Device Establishment Licence (MDEL) framework, publishing amendments to the Medical Devices Regulations in the Canada Gazette, Part II on June 17, 2026.
The amendments (SOR/2026-110) come into force on December 14, 2026, giving industry a six-month implementation period to prepare.
While Health Canada’s announcement highlights three principal regulatory changes, a comparison of Guidance on Medical Device Establishment Licensing (GUI-0016) Version 9 (September 2023) and the newly published Version 11 (June 2026) reveals a broader modernization of licensing expectations, supply chain transparency, and inspection readiness.
For importers, distributors, and Class I manufacturers, these updates are more than administrative—they provide a clearer picture of what Health Canada expects during licence reviews and inspections.
This announcement represents the completion of Phase 2 of Health Canada’s MDEL modernization initiative.
The first phase, which came into force in December 2024, focused primarily on strengthening compliance and enforcement by introducing measures such as Terms and Conditions on MDELs, updated recall provisions, and modernized licensing processes.
Phase 2 shifts the focus toward reducing unnecessary regulatory burden while improving visibility across the Canadian medical device supply chain.
The final amendments closely follow the proposals released for consultation in late 2025, indicating that Health Canada largely proceeded with the changes as originally proposed.
1. Foreign Distributors No Longer Need an MDEL in Certain Circumstances
Perhaps the most significant change removes the requirement for many foreign distributors to maintain their own MDEL.
Under the updated regulations, foreign distributors that sell medical devices only through Canadian importers holding a valid MDEL no longer require their own licence.
This reduces administrative burden while maintaining regulatory oversight through the Canadian importer responsible for bringing products into Canada.
2. Supplier Lists Become Mandatory
Version 11 introduces a new requirement for applicants and licence holders to provide supplier information.
Supplier lists must now accompany new MDEL applications and be reviewed and updated annually during the Annual Licence Review.
This provides Health Canada with greater visibility into the medical device supply chain while improving traceability during inspections, investigations, and recalls.
3. Documented Procedures Become an Explicit Regulatory Requirement
Historically, applicants signed attestations confirming procedures existed.
The updated framework now requires organizations to establish, implement and maintain documented procedures as an explicit regulatory obligation.
While many organizations already maintain these procedures through their quality systems, the revised wording reflects Health Canada’s observation that attestations were not always supported by documented evidence during inspections.
| Topic | Version 9 (Sept. 2023) | Version 11 (June 2026) | Practical Impact |
| Foreign distributors | Generally required to hold an MDEL when selling into Canada. | Exempt when selling solely through a Canadian importer holding an MDEL. | Reduces regulatory burden for many international suppliers. |
| Supplier reporting | Manufacturers identified; supplier reporting was limited. | Supplier lists are mandatory with applications and Annual Licence Reviews. | Greater supply chain transparency and improved traceability. |
| Documented procedures | Compliance demonstrated primarily through signed attestations. | Organizations must establish, implement and maintain documented procedures. | Increased emphasis on inspection readiness and evidence-based compliance. |
| Supplier visibility | Limited regulatory visibility into supplier relationships. | Supplier information becomes a formal licensing requirement. | Better oversight during recalls and investigations. |
| Inspection expectations | Inspectors verified attested procedures. | Inspectors can assess explicit regulatory obligations for documented procedures. | Higher expectations for SOP governance and implementation. |
| Importer/distributor examples | Fewer practical licensing scenarios. | Expanded activity examples clarify who does and does not require an MDEL. | Easier interpretation of licensing obligations. |
| Class I manufacturer exemptions | Existing exemptions described, but less clearly. | Updated examples clarify when Class I manufacturers remain exempt if selling through an MDEL holder. | Reduced uncertainty for manufacturers entering Canada. |
| Medical device authorizations | Primarily references MDLs. | References additional authorization pathways and urgent public health authorizations. | Reflects today’s broader regulatory landscape. |
| Supply chain oversight | Focused primarily on manufacturers. | Explicit recognition of suppliers as regulated information. | More comprehensive oversight of imported devices. |
| Terminology and guidance | Based on the regulatory framework prior to modernization. | Updated terminology aligns with recent amendments and modern compliance practices. | Greater consistency across Health Canada’s guidance documents. |
Although the changes appear modest at first glance, they reinforce Health Canada’s continuing shift toward risk-based oversight.
Rather than imposing additional licensing requirements, Health Canada has reduced regulatory burden where it provides little public health value—such as requiring certain foreign distributors to maintain an MDEL—while increasing expectations around documentation, supply chain transparency, and inspection readiness.
Organizations should not view these amendments as simply administrative updates.
The explicit requirement for documented procedures and mandatory supplier reporting suggests Health Canada expects companies to demonstrate stronger internal governance and greater visibility across their supply chains.
The six-month implementation period should be viewed as preparation time—not a grace period after implementation.
Organizations should consider:
Companies that begin preparing now will be better positioned for future inspections and annual licence reviews.
Whether you’re applying for a new Medical Device Establishment Licence, preparing for an Annual Licence Review, or assessing how these amendments affect your Canadian regulatory strategy, dicentra’s regulatory specialists can help.
Our team supports manufacturers, importers, and distributors with:
If your organization imports or distributes medical devices in Canada, contact us now toreview your MDEL program before the new requirements take effect on December 14, 2026.